Durable responses to triplet immunotherapy targeting TGF-β, PD-L1, and tumor antigen, with an IL-15 receptor superagonist in mismatch repair proficient castration-resistant prostate cancer.
- DOI
- 10.1136/jitc-2026-015336
- Published
- 2026 Jul 24
- Container
- Journal for immunotherapy of cancer
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1136/jitc-2026-015336,
title = {Durable responses to triplet immunotherapy targeting TGF-β, PD-L1, and tumor antigen, with an IL-15 receptor superagonist in mismatch repair proficient castration-resistant prostate cancer.},
author = {Redman JM and Madan RA and Donahue RN and Toney NJ and Karzai F and Strauss J and Palena C and Horn LA and Del Rivero J and Marté JL and Cordes L and Lynch MT and Meyer TJ and Cam M and Soon-Shiong P and Schlom J and Gulley JL},
year = {2026},
journal = {Journal for immunotherapy of cancer},
doi = {10.1136/jitc-2026-015336},
url = {https://doi.org/10.1136/jitc-2026-015336}
}RIS
TY - JOUR TI - Durable responses to triplet immunotherapy targeting TGF-β, PD-L1, and tumor antigen, with an IL-15 receptor superagonist in mismatch repair proficient castration-resistant prostate cancer. AU - Redman JM AU - Madan RA AU - Donahue RN AU - Toney NJ AU - Karzai F AU - Strauss J AU - Palena C AU - Horn LA AU - Del Rivero J AU - Marté JL AU - Cordes L AU - Lynch MT AU - Meyer TJ AU - Cam M AU - Soon-Shiong P AU - Schlom J AU - Gulley JL PY - 2026 JO - Journal for immunotherapy of cancer DO - 10.1136/jitc-2026-015336 UR - https://doi.org/10.1136/jitc-2026-015336 ER -
APA
JM, R., RA, M., RN, D., NJ, T., F, K., J, S., C, P., LA, H., J, D. R., JL, M., L, C., MT, L., TJ, M., M, C., P, S., J, S., & JL, G. (2026). Durable responses to triplet immunotherapy targeting TGF-β, PD-L1, and tumor antigen, with an IL-15 receptor superagonist in mismatch repair proficient castration-resistant prostate cancer.. Journal for immunotherapy of cancer. https://doi.org/10.1136/jitc-2026-015336
Source records
- pubmed · retrieved 2026-09-27T15:56:09.989Z